Profile data is unavailable for this security.
About the company
SeQuent Scientific Limited is an India-based animal health company. The Company provides a wide range of animal health products, including finished dose formulations, active pharmaceutical ingredients (APIs), as well as analytical services. The Company operates through the pharmaceuticals segment. The Company is focused on various therapies, such as targeted are anthelmintics (endo and ecto parasiticides), anti-protozoals, nutraceuticals, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-infectives and dermatology. It is specialized in analytical and bio analytical services to support the API, pharmaceutical, personal care and nutraceutical companies. It provides analytical solutions, including method validation, stability, microbiology for APIs and finished products in a variety of dosage forms as per pharmacopoeia monographs, customer developed methods or in-house method development. The Company’s subsidiaries include Alivira Animal Health Limited and SeQuent Research Limited.
- Revenue in INR (TTM)14.49bn
- Net income in INR164.77m
- Incorporated1985
- Employees1.20k
- LocationSeQuent Scientific Ltd301/A, 3rd Floor,Dosti Pinnacle,, Plot No.E7,Road No. 22MUMBAI 400604IndiaIND
- Phone+91 2 241114777
- Fax+91 2 241114754
- Websitehttps://sequent.in/
More ▼
Mergers & acquisitions
| Acquired company | SEQUENT:NSI since announced | Transaction value |
|---|---|---|
| Viyash Life Sciences Pvt Ltd | 6.86% | -- |
Data delayed at least 15 minutes, as of Nov 25 2024 10:19 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Indoco Remedies Ltd | 17.73bn | 320.40m | 29.49bn | 5.93k | 95.93 | 2.71 | 21.64 | 1.66 | 3.34 | 3.34 | 175.26 | 118.23 | 0.8194 | 1.52 | 4.51 | 2,989,727.00 | 1.36 | 6.88 | 1.99 | 9.85 | 68.34 | 65.59 | 1.66 | 6.93 | 0.8142 | 1.71 | 0.4339 | 14.02 | 8.91 | 13.41 | -30.78 | -- | 34.54 | 37.97 |
| RPG Life Sciences Limited | 6.18bn | 706.60m | 32.94bn | 1.27k | 46.62 | 8.68 | 36.65 | 5.33 | 42.72 | 42.72 | 373.86 | 229.38 | 1.22 | 1.99 | 8.44 | 4,868,662.00 | 13.92 | 16.07 | 19.35 | 21.77 | 67.85 | 62.99 | 11.43 | 11.99 | 1.45 | 207.32 | 0.00 | 29.27 | 13.50 | 12.01 | 29.60 | 51.98 | 28.60 | 46.14 |
| Dishman Carbogen Amcis Ltd | 26.19bn | -1.74bn | 35.82bn | 1.13k | -- | 0.6243 | 40.56 | 1.37 | -11.09 | -11.09 | 166.94 | 365.90 | 0.2661 | 0.6339 | 4.45 | 23,132,690.00 | -1.77 | -0.3986 | -2.21 | -0.4888 | 78.75 | 73.83 | -6.65 | -1.54 | 0.6001 | -0.0583 | 0.3041 | -- | 8.41 | 4.91 | -414.93 | -- | -0.3175 | -- |
| Gufic BioSciences Ltd | 8.04bn | 849.28m | 40.51bn | 1.45k | 47.65 | 7.05 | 39.71 | 5.04 | 8.48 | 8.48 | 80.23 | 57.26 | 0.7751 | 1.98 | 2.79 | 5,550,852.00 | 8.19 | 11.46 | 12.66 | 19.21 | 53.37 | 45.79 | 10.57 | 10.46 | 1.11 | 7.70 | 0.3401 | 1.31 | 16.80 | 18.12 | 8.07 | 31.46 | 53.83 | 14.87 |
| Morepen Laboratories Ltd | 17.61bn | 1.31bn | 40.51bn | 1.62k | 29.10 | 3.65 | 25.74 | 2.30 | 2.54 | 2.54 | 34.07 | 20.27 | 1.28 | 4.21 | 6.02 | 10,847,620.00 | 9.56 | 7.90 | 13.28 | 13.34 | 38.57 | 33.34 | 7.48 | 5.49 | 1.99 | 31.88 | 0.0293 | 0.00 | 19.25 | 17.08 | 148.63 | 27.22 | 47.03 | -- |
| Aarti Drugs Ltd | 23.80bn | 1.52bn | 41.00bn | 1.06k | 27.03 | 3.21 | 19.94 | 1.72 | 16.62 | 16.62 | 259.74 | 139.96 | 0.9954 | 3.16 | 3.43 | 22,364,630.00 | 6.37 | 9.73 | 9.62 | 15.78 | 34.60 | 22.23 | 6.40 | 8.25 | 1.01 | 6.83 | 0.3159 | -- | -6.90 | 10.13 | 3.07 | 13.82 | 24.96 | -- |
| Solara Active Pharma Sciences Ltd | 12.22bn | -5.36bn | 44.11bn | 2.16k | -- | 2.65 | -- | 3.61 | -137.13 | -137.13 | 320.29 | 301.63 | 0.4731 | 1.77 | 2.69 | 5,667,023.00 | -20.76 | -2.44 | -36.40 | -3.84 | 38.70 | 41.16 | -43.89 | -4.49 | 0.448 | -1.30 | 0.4355 | -- | -10.73 | -1.45 | -2,458.12 | -- | -4.81 | -- |
| Hikal Ltd | 18.21bn | 735.12m | 48.22bn | 2.06k | 65.68 | 4.01 | 24.31 | 2.65 | 5.95 | 5.95 | 147.30 | 97.60 | 0.7509 | 2.37 | 4.27 | 8,837,312.00 | 3.03 | 5.07 | 4.26 | 7.51 | 54.14 | 46.78 | 4.04 | 5.86 | 0.8421 | 2.46 | 0.3919 | 12.19 | -11.79 | 2.34 | -11.20 | -7.55 | 9.72 | 0.00 |
| Jeena Sikho Lifecare Ltd | -100.00bn | -100.00bn | 48.40bn | 1.23k | -- | 153.08 | -- | -- | -- | -- | -- | 12.72 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.8228 | -- | 0.2681 | -- | 43.84 | -- | 77.37 | -- | -- | -- |
| SeQuent Scientific Ltd | 14.49bn | 164.77m | 50.39bn | 1.20k | 309.17 | 7.42 | 54.40 | 3.48 | 0.6537 | 0.6537 | 57.25 | 27.23 | 0.9464 | 2.28 | 4.46 | 12,129,000.00 | 1.79 | 1.09 | 2.94 | 1.76 | 45.86 | 41.97 | 1.89 | 1.18 | 0.9564 | 1.26 | 0.3974 | 35.06 | -3.60 | 5.68 | 70.40 | -- | 6.96 | -- |
| Innova Captab Ltd | 11.78bn | 1.18bn | 58.10bn | -- | 40.55 | 6.49 | 42.56 | 4.93 | 25.04 | 25.04 | 232.86 | 156.45 | 0.903 | 4.83 | 3.74 | -- | 9.07 | 10.82 | 12.50 | 18.38 | 34.06 | 25.18 | 10.05 | 8.04 | 1.32 | 19.79 | 0.2259 | -- | 16.72 | 24.90 | 38.84 | 36.55 | 104.14 | -- |
| Aarti Pharmalabs Ltd | 19.68bn | 2.28bn | 59.22bn | 1.63k | 25.96 | 3.19 | 19.29 | 3.01 | 25.16 | 25.16 | 217.12 | 204.88 | 0.7733 | 1.62 | 4.59 | 12,095,750.00 | 8.96 | -- | 11.86 | -- | 45.56 | -- | 11.59 | -- | 0.9611 | 17.12 | 0.1723 | -- | -4.76 | -- | 12.10 | -- | -- | -- |
| Unichem Laboratories Ltd | 17.75bn | -55.72m | 60.40bn | 3.19k | -- | 2.52 | 56.82 | 3.40 | -0.7948 | -0.7948 | 251.56 | 340.97 | 0.5563 | 0.9064 | 2.85 | 5,556,270.00 | -0.1747 | -1.67 | -0.2226 | -2.03 | 62.33 | 56.18 | -0.314 | -3.99 | 1.20 | 2.77 | 0.1111 | -- | 26.94 | 7.64 | 65.15 | -- | -35.00 | -- |
| Supriya Lifescience Ltd | 6.25bn | 1.58bn | 64.94bn | 448.00 | 41.29 | 7.17 | 37.15 | 10.39 | 19.54 | 19.54 | 77.55 | 112.56 | 0.6737 | 2.01 | 6.56 | 13,950,510.00 | 16.98 | 19.08 | 18.38 | 24.04 | 66.81 | 57.12 | 25.20 | 24.71 | 4.05 | 111.46 | 0.006 | 2.88 | 23.74 | 15.47 | 32.56 | 24.75 | 83.79 | -- |
| Sun Pharma Advanced Research Co Ltd | 600.85m | -4.09bn | 66.36bn | 409.00 | -- | -- | -- | 110.45 | -12.60 | -12.60 | 1.85 | -2.38 | 0.1216 | -- | 2.66 | 1,469,078.00 | -82.71 | -61.70 | -164.56 | -119.31 | 51.18 | 74.49 | -680.16 | -163.40 | -- | -145.15 | 4.25 | -- | -68.36 | -16.21 | -73.96 | -- | 15.40 | -- |
Data as of Nov 25 2024. Currency figures normalised to SeQuent Scientific Ltd's reporting currency: Indian Rupee INR
15.08%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| quant Money Managers Ltd.as of 31 Oct 2024 | 21.88m | 8.77% |
| UTI Asset Management Co. Ltd. (Investment Management)as of 30 Jun 2024 | 8.31m | 3.33% |
| White Oak Capital Partners Pte Ltd.as of 30 Jun 2024 | 4.08m | 1.63% |
| SSgA Funds Management, Inc.as of 07 Nov 2024 | 1.34m | 0.54% |
| Dimensional Fund Advisors LPas of 07 Nov 2024 | 1.13m | 0.45% |
| The Caisse de d�p�t et placement du Qu�becas of 31 Dec 2023 | 554.31k | 0.22% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 Oct 2024 | 269.94k | 0.11% |
| Dimensional Fund Advisors Ltd.as of 31 Aug 2024 | 42.27k | 0.02% |
| DFA Australia Ltd.as of 30 Sep 2024 | 32.45k | 0.01% |
| American Century Investment Management, Inc.as of 07 Nov 2024 | 4.92k | 0.00% |
More ▼
Data from 30 Jun 2023 - 15 Nov 2024Source: FactSet Research Systems Inc.
